What We Offer
Our Products
WELL life™
Product Overview
WELL life™ SARS-CoV-2/Flu A+B Rapid Antigen Point-of-Care Test is a lateral flow immunoassay intended for in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, influenza A and influenza B directly from anterior nasal swab specimens obtained from patients who are suspected of COVID-19 by their healthcare provider, within the first five days of onset of symptoms.
- 1 sample - 3 results
- SARS-CoV-2/Flu A+B Rapid POC Combo Antigen Test
- Simultaneous testing for acute respiratory infections caused by COVID-19, Flu A, Flu B
- Lateral flow immunoassay
- Covid-19: PPA 87.5%; NPA 99.7%
- Flu A: PPA 85.9%; NPA 99.7%
- Flu B: PPA 86.8%; NPA 99.7%
- Nasal or nasopharyngeal swab samples
- Delivers results in 10 minutes
- No equipment necessary
- CLIA Waived Test
RCS Healthcare: Our Vision